Cargando…

Pilot study evaluating the efficacy of a topical formulation containing emodepside and praziquantel in the treatment of natural feline troglostrongylosis

BACKGROUND: Troglostrongylus brevior, a lungworm usually affecting wild felids, has been recently recorded in a number of cases in domestic cats, mainly in Mediterranean areas. Although feline troglostrongylosis is a severe and life-threatening disease, especially in young cats, treatment options ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Traversa, Donato, Veronesi, Fabrizia, Danesi, Patrizia, Morelli, Simone, Crisi, Paolo E., Morganti, Giulia, Iorio, Raffaella, Pampurini, Fabrizio, Schaper, Roland, Santoro, Azzurra, Paoletti, Barbara, Di Cesare, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417080/
https://www.ncbi.nlm.nih.gov/pubmed/30867041
http://dx.doi.org/10.1186/s13071-019-3361-7
_version_ 1783403494446727168
author Traversa, Donato
Veronesi, Fabrizia
Danesi, Patrizia
Morelli, Simone
Crisi, Paolo E.
Morganti, Giulia
Iorio, Raffaella
Pampurini, Fabrizio
Schaper, Roland
Santoro, Azzurra
Paoletti, Barbara
Di Cesare, Angela
author_facet Traversa, Donato
Veronesi, Fabrizia
Danesi, Patrizia
Morelli, Simone
Crisi, Paolo E.
Morganti, Giulia
Iorio, Raffaella
Pampurini, Fabrizio
Schaper, Roland
Santoro, Azzurra
Paoletti, Barbara
Di Cesare, Angela
author_sort Traversa, Donato
collection PubMed
description BACKGROUND: Troglostrongylus brevior, a lungworm usually affecting wild felids, has been recently recorded in a number of cases in domestic cats, mainly in Mediterranean areas. Although feline troglostrongylosis is a severe and life-threatening disease, especially in young cats, treatment options are very limited. The present study evaluated the efficacy and safety of a spot-on formulation containing emodepside 2.1% and praziquantel 8.6% (Profender(®), Bayer), which is licensed for treatment of the more common cat lungworm Aelurostrongylus abstrusus, for the treatment of natural troglostrongylosis. METHODS: Sixteen cats enrolled in the study were 1:1 allocated to two groups, i.e. Group T, treated with Profender(®) spot-on on days 0 and 14 (± 2) at the recommended clinical dose, and Group C which remained untreated. After study completion, the control cats received two rescue treatments with Profender(®) on days 28 (± 2) and 42 (± 2). The primary efficacy criterion was the absence of T. brevior L1 following treatment. Other efficacy parameters were the quantitative comparison of L1 presence before (baseline) and after treatment in both groups, and the comparison of clinical signs pre- and post-treatment. RESULTS: In terms of stopping larval shedding, Profender(®) showed an efficacy of 97% and 97.5% (arithmetic and geometric means, respectively) for group T, 97.1% and 98.5% for group C after one administration, and 100% for both groups after two doses. Overall, 12 cats showed clinical signs related to T. brevior. Specifically, 9 were clinically affected before treatment while clinical signs appeared after the first treatment in 3 cats. At the end of the study, all symptomatic cats fully recovered with the exception of 3 cats that showed clinical signs similar to those observed at the pre-treatment examination at the end of the study. CONCLUSIONS: This study shows that Profender(®) is effective against T. brevior.
format Online
Article
Text
id pubmed-6417080
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64170802019-03-25 Pilot study evaluating the efficacy of a topical formulation containing emodepside and praziquantel in the treatment of natural feline troglostrongylosis Traversa, Donato Veronesi, Fabrizia Danesi, Patrizia Morelli, Simone Crisi, Paolo E. Morganti, Giulia Iorio, Raffaella Pampurini, Fabrizio Schaper, Roland Santoro, Azzurra Paoletti, Barbara Di Cesare, Angela Parasit Vectors Research BACKGROUND: Troglostrongylus brevior, a lungworm usually affecting wild felids, has been recently recorded in a number of cases in domestic cats, mainly in Mediterranean areas. Although feline troglostrongylosis is a severe and life-threatening disease, especially in young cats, treatment options are very limited. The present study evaluated the efficacy and safety of a spot-on formulation containing emodepside 2.1% and praziquantel 8.6% (Profender(®), Bayer), which is licensed for treatment of the more common cat lungworm Aelurostrongylus abstrusus, for the treatment of natural troglostrongylosis. METHODS: Sixteen cats enrolled in the study were 1:1 allocated to two groups, i.e. Group T, treated with Profender(®) spot-on on days 0 and 14 (± 2) at the recommended clinical dose, and Group C which remained untreated. After study completion, the control cats received two rescue treatments with Profender(®) on days 28 (± 2) and 42 (± 2). The primary efficacy criterion was the absence of T. brevior L1 following treatment. Other efficacy parameters were the quantitative comparison of L1 presence before (baseline) and after treatment in both groups, and the comparison of clinical signs pre- and post-treatment. RESULTS: In terms of stopping larval shedding, Profender(®) showed an efficacy of 97% and 97.5% (arithmetic and geometric means, respectively) for group T, 97.1% and 98.5% for group C after one administration, and 100% for both groups after two doses. Overall, 12 cats showed clinical signs related to T. brevior. Specifically, 9 were clinically affected before treatment while clinical signs appeared after the first treatment in 3 cats. At the end of the study, all symptomatic cats fully recovered with the exception of 3 cats that showed clinical signs similar to those observed at the pre-treatment examination at the end of the study. CONCLUSIONS: This study shows that Profender(®) is effective against T. brevior. BioMed Central 2019-03-12 /pmc/articles/PMC6417080/ /pubmed/30867041 http://dx.doi.org/10.1186/s13071-019-3361-7 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Traversa, Donato
Veronesi, Fabrizia
Danesi, Patrizia
Morelli, Simone
Crisi, Paolo E.
Morganti, Giulia
Iorio, Raffaella
Pampurini, Fabrizio
Schaper, Roland
Santoro, Azzurra
Paoletti, Barbara
Di Cesare, Angela
Pilot study evaluating the efficacy of a topical formulation containing emodepside and praziquantel in the treatment of natural feline troglostrongylosis
title Pilot study evaluating the efficacy of a topical formulation containing emodepside and praziquantel in the treatment of natural feline troglostrongylosis
title_full Pilot study evaluating the efficacy of a topical formulation containing emodepside and praziquantel in the treatment of natural feline troglostrongylosis
title_fullStr Pilot study evaluating the efficacy of a topical formulation containing emodepside and praziquantel in the treatment of natural feline troglostrongylosis
title_full_unstemmed Pilot study evaluating the efficacy of a topical formulation containing emodepside and praziquantel in the treatment of natural feline troglostrongylosis
title_short Pilot study evaluating the efficacy of a topical formulation containing emodepside and praziquantel in the treatment of natural feline troglostrongylosis
title_sort pilot study evaluating the efficacy of a topical formulation containing emodepside and praziquantel in the treatment of natural feline troglostrongylosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417080/
https://www.ncbi.nlm.nih.gov/pubmed/30867041
http://dx.doi.org/10.1186/s13071-019-3361-7
work_keys_str_mv AT traversadonato pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis
AT veronesifabrizia pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis
AT danesipatrizia pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis
AT morellisimone pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis
AT crisipaoloe pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis
AT morgantigiulia pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis
AT iorioraffaella pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis
AT pampurinifabrizio pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis
AT schaperroland pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis
AT santoroazzurra pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis
AT paolettibarbara pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis
AT dicesareangela pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis